Good morning, everyone. A shiny day is unfolding here on the Pharmalot corporate campus, where we are scurrying to get the short people to their assorted destinations. Wish us luck. To cope, yes, we are quaffing a cup or three of stimulation. Our flavor today - Southern Pecan. Please join us as we all brace for another round of meetings, deadlines and research. Hope your day goes well and you conquer the world, so to speak...
That New Lupus Drug, Benlysta, Gets Mixed Review (Washington Post)
Pfizer Puts 'Discovery Park,' Where Viagra Was Discovered, Up For Sales (Reuters)
Research Funding Grows Scarcer For Biotechs: Report (Bloomberg News)
Pfizer May Get Settlement From Orangetown NY Over Property Taxes (LoHud)
Actavis Scours Emerging Markets For Partners (Bloomberg News)
Glaxo Buys China Flu Vaccine Joint Venture (InPharma Technologist)
Synageva BioPharma Will Buy Trimeris (Raleigh News & Observer)
Bristol And Sanofi In Race For Marketing Pact With Biocon (Economic Times)
Glaxo CEO Sees Strong Interest In OTC Products Sale (Reuters)
Merck And South Korea's Hanwha To Commercialize Enbrel (Pharma Times)
Is Pharma Research Into Depression And Schizophrenia Dwindling? (The Guardian)
FTC Seeks More Info On Teva And Cephalon Deal (Reuters)
UK Updates Its Patent Box Initiative (Pharma Times)
EDITOR’S NOTE: Please check this post for updates throughout the morning
1 Comment
Re: Depression and Schizophrenia Research
I have seen this statement several times recently that there have been no or only one new antidepressant approved in the last 10 years. This is false. I can think of several
Cymbalta August 3, 2004
Emsam February 27, 2006
Pristiq February 29, 2008
Valdoxan February 20009
(not counting 3 antipsychotics as add-ons) and there may be more, that I can't think of.
Coming from such knowledgable individuals this may simply be evidence laying the groundwork for a new campaign to lower standards or gain some other concessions.
Salmon